DDInter1340 DDInter1940
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Omeprazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Omeprazole {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Omeprazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Omeprazole {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) downregulates {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vismodegib
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) downregulates {v} (Gene) and {u} (Diease) associated with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Vismodegib
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Omeprazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)
Omeprazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Omeprazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Omeprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Omeprazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Omeprazole (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Tolvaptan (Compound) and Tolvaptan (Compound) resembles Vismodegib (Compound)
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) downregulates ALB (Gene) and ALB (Gene) is bound by Vismodegib (Compound)
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) downregulates ABCB1 (Gene) and kidney cancer (Diease) associated with ABCB1 (Gene) and ABCB1 (Gene) is bound by Vismodegib (Compound)
Omeprazole (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is downregulated by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)